13F Holdings
中文EN

AIBT AIBOTICS THERAPIES, INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1763329 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-3.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-241.3%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets937.3%
Debt / equity—
Current ratio0.05x
Interest coverage-9.75x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-201.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2,183$0———
Gross profit$2,183$0———
SG&A expense$1.85M$1.63M$616,724$1.74M$4.99M
Operating income-$1.84M-$1.63M-$616,724-$1.74M-$4.99M
Interest expense$226,902$213,458$564,623$863,330$143,057
Pretax income-$2.22M-$1.85M-$1.18M-$2.61M-$5.14M
Income tax$0$0$0$0$0
Net income-$2.22M-$1.85M-$1.18M-$2.61M-$5.14M
EBITDA-$1.84M-$1.63M-$615,726-$1.74M-$4.99M
EPS (diluted)—————
Weighted avg. shares (diluted)————13.41M
Balance sheet
Cash & equivalents$255,940$185,097$279,134$385,899$1.27M
Inventory$0————
Current assets$270,107$185,097$279,134$385,899$1.27M
PP&E, net$0$0$498$1,496$2,497
Intangibles—$1.27M———
Total assets$874,673$1.46M$2.22M$387,395$1.27M
Current liabilities$4.79M$4.85M$4.25M$764,513$594,370
Total liabilities$4.83M$4.85M$4.25M$1.28M$1.22M
Shareholders' equity-$3.96M-$3.39M-$2.03M-$891,348$52,021
Shares outstanding486.90M39.99M14.90M14.86M13.97M
Cash flow statement
Operating cash flow-$458,240-$259,037-$106,765-$656,620-$235,482
Capital expenditure———$0$2,746
Free cash flow———-$656,620-$238,228
Investing cash flow——$0$0-$2,746
Financing cash flow$529,083$165,000$0-$225,000$1.40M
Depreciation & amortization$0$498$998$1,001$249
Stock-based compensation—$0$635$1.02M$4.31M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.